4574 — Taiko Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥19bn
- ¥17bn
- ¥6bn
2019 March 31st | 2020 March 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
Standards: | JAS | JAS | JAS | JAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10,419 | 14,966 | 11,299 | 5,040 | 6,120 |
Cost of Revenue | |||||
Gross Profit | 7,203 | 10,608 | 3,326 | 1,079 | 2,577 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8,503 | 11,270 | 20,125 | 9,961 | 10,028 |
Operating Profit | 1,915 | 3,696 | -8,826 | -4,921 | -3,908 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,986 | 3,504 | -8,887 | -4,869 | -3,563 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,415 | 2,453 | -9,593 | -4,894 | -3,610 |
Net Income Before Extraordinary Items | |||||
Net Income | 1,415 | 2,453 | -9,593 | -4,894 | -3,610 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,415 | 2,453 | -9,594 | -4,895 | -3,611 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 31.3 | 59.4 | -163 | -84.8 | -37.4 |
Dividends per Share | |||||
Special Dividends per Share |